Zusammenfassung
Die Monoaminoxidase (EC 1.4.3.4; Amin: Sauerstoff-Oxidoreduktase (desaminierend) (MAO), ein Enzym der äußeren Mitochondrienmembran, oxidiert eine Reihe von monoaminergen Neurotransmittern und Neuromodulatoren sowie exogene bioaktive Monoamine nach folgender ReaktionsGleichung: RCH2NH2+O2+H2O→RCHO+NH3+H2O2 Aufgrund unterschiedlicher Substratspezifität und Inhibitorsensitivität wurde die Existenz zweier multipler Formen postuliert (Abb. 4.1.1; Johnston 1968, zur Übersicht: Youdim et al. 1988): Während MAO-A vorwiegend Serotonin und Noradrenalin desaminiert und selektiv durch Clorgylin inhibiert wird, besitzt die MAO-B eine höhere Affinität zu Benzylamin und β-Phenethylamin und wird selektiv durch (R)-Deprenyl inhibiert; Dopamin und Tyramin sind Substrate für beide Enzymformen; wobei Dopamin im menschlichen Gehirn eine etwas höhere Affinität für MAO-B aufweist (Riederer und Youdim 1986).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC (1988) c DNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85: 4934–4938
Prada M, Kettler R, Keller HH, Burkard WP(1988) RO 19–6327, a resersible, highly selective inhibitor of type B monoamine oxidase, completely devoid of tyramine-potentiating effects: comparison with selegiline. Neurol Neurobiol 42B: 359–363
Prada M, Keller HH, Kettler R (1989) Vergleich der neuen MAO-A-Hemmer Moclobemid und Toloxaton mit Tranylcypromin im Tierversuch: Bedeutung für die Praxis. In: Laux G, Riederer P (Hrsg) Neue selektive Monoaminoxidase-Hemmer in der Therapie depressiver Erkrankungen. Psychiat Prax [Sonderheft I] 16: 18–24
Denney RM, Patel NT, Fritz RR, Abell CW(1982) A monoclonal antibody elicited to human platelet monoamine oxidase. Isolation and specificity for human monoamine oxidase B but not A. Mol Pharmacol 22: 500–508
Dollery CT, Davies DS, Strolin-Benedetti M(1982) Clinical pharmacology of MD 780515, a selective and reversible MAO-A inhibitor. In: Kamijo K, Usdin E, Nagatsu T (eds) Monoamine oxidase, basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 221–229
Dollery CT, Brown MJ, Davies DS, Strolin-Benedetti M(1984) Pressor amines and monoamines oxidase ihibitors. In: Tipton KF, Dostert P, Strolin-Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp 429–441
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297
Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic `suicide` and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73: 55–64
Keller HH, Kettler R, Keller G, DA Prada M (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16–6491. Naunyn Schmiedebergs Arch Pharmacol 335: 15–20
Knoll J (1986) The pharmacology of de- prenyl. J Neural Transm [Suppl] 22: 75–89
Konradi C, Riederer P, Heinsen H (1989) Histo chemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease? In: Przuntek H, Riede-Rer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 243–248
Laux G, Riederer P (Hrsg) (1989) Neue selektive Monoaminoxidase-Hemmer in der Therapie depressiver Erkrankungen. Psychiat Prax [Sonderheft I] 16: 1–50
Moller HJ, Wendt G (1989) Brofaromin — ein selektiver, reversibler und kurzwirksamer MAO-A-Hemmer. In: Laux G, Riederer P (Hrsg) Neue selektive Monoaminoxidase-Hemmer in der Therapie depressiver Erkrankungen. Psychiat Prax [Sonderheft I 1 16: 32–37
Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem 46: 1359–1365
Riederer P, Przuntek H (1988) Morbus Parkinson- Selegilin (R-Deprenyl; MoverganR). Ein neues Therapiekonzept. Springer, Wien New York
Riederer P, Youdim MBH, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 43: 217–226
Robinson DS, Kayser A, Corcella D, Laux G, Mingling K, Howard D (1985) Panic attacks in out-patients with depression: response to antidepressant treatment. Psychopharmacol Bull 21: 562–567
Tariot PN, Sunderland T, Weingartner H, Murpi-Iy Dl, Welkowitz JA, Thompson K, Cohen RM (1987) Cognitive effects of L-deprenyl in Alzheimer’s disease. Psychopharmacology 91: 489–495
Tipton KF, Mantle TJ (1981) Inhibition of rat liver monoamine oxidase by clorgyline and deprenyl. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors: the state of the art. Wiley, Chichester, pp 3–27
Youdim MBH, Finberg JPM (1986) MAO Type B inhibitors as adjunct to L-DOPA therapy. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 127–136
Youdim MBH, Finberg JPM, Tipton KF (1988) Monoamine oxidase. In: TRENDELENBURG U, WEINER N (eds) Catecholamines I. Springer, Berlin Heidelberg New York Tokyo, pp 119–192 (Handbook Exp Pharmacol, vol 90/I)
Zreika M, Fozard JR, Dudley MW, Bey PH, Mcdonald IA, Palfreyman MG (1989) MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson’s disease. J Neural Transm [P-D Sect] 1: 243–254
Alvan G, Grind M, Graffner C, SjÖqvist F (1984) Relationship of N-demethylation of amiflami- ne and its metabolite to debrisoquine hy- droxylation polymorphism. Clin Pharmacol Ther 36: 515–519
Alvan G, Graffner C, Grind M, Gustafsson LL, Lindgreen JE, Nordin C, ross S, Selander H, Siwers B (1986) Tolerance and pilot pharmacokinetics of amiflamine after increasing sing-le oral doses in healthy subjects. Clin Pharmacol Ther 40: 81–85
Amrein R, Allen SR, Guentert TW, Hartmann D, Lorscheid T, Schoerlin M-P, Vranesic D (1989)The pharmacology of reversible monoamine oxidase inhibitors. B J Psychiatry 155 [Suppl 61: 66–71
Antonin KH, Jedrychowski M, Bieck PR (1990) Brofaromin: Pharmakodynamische und pharmakokinetische Untersuchungen an gesunden Probanden mit einem neuen reversiblen und selektiven Hemmstoff der MAO-A. Munch Med Wochenschr 132 [Suppl 1]: S13 — S17
Baker GB, Courts RT (1989) Metabolism of monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatryl3: 395–403
Baker GB, Hampson DR, Courrs RT, Micetich RG, Hall TW, Rao TS (1986) Detection and quantitation of a ring-hydroxylated metabolite of the antidepressant drug tranylcypromine. J Neural Transm 65: 233–243
Baselt RC, Stewart CB, Shaskan E (1977) Determination of serum and urine concentrations of tranylcypromine by electron-capture gasliquid chromatography. J Anal Tox 1: 215–217
Becker T, Laux G, Baumgarten F, Schoerlin MP, Ellinger T (1988) Time course of CSF and plasma pharmacokinetics and biogenic amines following oral administration of selective MAO-A inhibitors in depressed patients. J Psychopharmacol 2 (3–4): 1
BÉLanger P-M, Atitse-Gbeassor A(1982) Inhibitory effect of tranylcypromine on hepatic drug metabolism in the rat. Biochem Pharmacol 31: 2679–2683
Ben-Arie O, George GCW (1979) A case of tranylcypromine („Parnate“) addiction. Br J Psychiatry 135: 273–274
Bieck P, Antonin KH, Jedrychowski M (1983) Monoamine oxidase inhibition in healthy volunteers by CGP 11305A, a new specific inhibitor of MAO-A. Mod Probl Pharmacopsychiatry 19: 53–62
Bonbon DB, Rossignol P, Lepage-Goffioul G, Adens A, Gilot P, Breulet M (1979) L’effet antidepressif du Ro 11–1163, inhibiteur selectif de la MAO-A. Extraits du Compte Rendu du Congrès de Psychiatrie et de Neurologie de Langue Française. LXXVII Session Angers, pp 1281–1286
Bruce RB, Tumbull L Newman J, Pivrs J (1966) Metabolism of metaxalone. J Med Chem 9: 286–288
Caddy B, Tilstone WJ (1976) Phenelzine in urine: assay and relation to acetylator status. Br J Clin Pharmacol 3: 633–637
Casacchia M, Carolei A, Barba C, Frontini M,Rossi A, Meco G, Zylberman MR (1984) A placebo controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiatry 17: 122–125
Cooper TB, Robinson DS, Nies A (1978) Phenelzine measurement in human plasma sensitive GLC-ECD procedure. Comm Psychopharmacol 2: 505–512
DA Prada M, Keller HH, Kettler R, Schaffner R, Pieri M, Burkard WP, Korn A, Haefely WE (1982) Ro 11–1163, a specific and short acting MAO inhibitor with antidepressant properties. In: Kamijo K et al. (eds) Monoamine oxidase, basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 183–186
DA Prada M, Kettler R, Keller HH, Haefely WE (1983) Neurochemical effects in vitro and in vivo of the antidepressant Ro 11–1163, a specific and short acting MAO-A inhibitor. Mod Probl Pharmacopsychiatry 19: 231–245
Dollery CT, Davies DS, Strolin-Benedetti M (1982) Clinical pharmacology of MD 780515, a selective and reversible MAO-A inhibitor. In: Kamijo K et al. (eds) Monoamine oxidase, basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 221–229
Dollery CT, Brown MJ, Davies DS, Strolin-Bene-Detti M (1984) Pressor amines and monoamine oxidase inhibitors. In: TIPTON KF et al. (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, New York, pp 429–441
Dyck LE, Durden DA, Boulton AA (1985) Formation of 13-phenylethylamine from the antidepressant, f3-phenylethylhydrazine. Biochem Pharmacol 34: 1925–1929
Graffner C, Grind M, Gustafsson L, Lindgren JE, Nordin C, Ross S, Selander H (1983) Pharmacokinetics, metabolism and tolerance of ami-flamine, a new selective and reversible MAO inhibitor. II World Conference on Clinical Pharmacology and Therapeutics, Washington, D.C. (Abstract 493 )
Graffner G, Alvan G, Grind M, Lake-Bakaar D, Lindgren JE, Lundstroem J, Selander H (1984) Pharmacokinetics and metabolism of amiflamine in rat, dog and man. In: TIPTON KF et al. (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, New York, pp 194–201
Grind M, Siwers B, Graffner C, Alvan G, Gustaffson LL, Helleday J, Lindgreen JE, Ogenstad S, Selander H (1986) Pressor response of oral tyramine in healthy men given amiflamine and placebo. Clin Pharmacol Ther 40: 155–160
Guentert TW(1968) Pharmacokinetics of benzodiazepines and of their metabolites. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 8. Taylor and Francis, London Philadelphia, pp 241–386
Hampson DR, Baker GB, Colts RT (1986) A comparison of the neurochemical properties of the stereoisomers of tranylcypromine in the central nervous system. Cell Mol Biol 32 (5): 593–599
Hansch C, Leo A (1979) Substituent constants for correlation analysis in chemistry and biology. Wiley Interscience, New York
Hengen N, Jedrychowski M, Hoffmann E (1984) Pharmacokinetics of CGP 11305 A in man after acute and prolonged or treatment. In: Tipton KF et al. (eds) Monoamine oxidase and disease. Prospects of therapy with reversible inhibitors. Academic Press, New York, pp 185–191
Holsboer F, Gerken A, Steiger A, Benkert O (1983) Antidepressive effects of CGP 11305 A, a competitive selective and short-acting MAO-A inhibitor. II World Conference on Clinical Pharmacology and Therapeutics, Washington, D.C. (Abstract 513 )
Johnston JP (1968) Some observation upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297
Lang A, Geissler HE, Mutschler E (1978) Fluori-metrische Bestimmung von Tranylcypromin in Plasma als 1-Dimethylamino-naphthalin-Ssulfonsäure-Derivat durch direkte quantitative Dünnschichtchromatographie. Drug Res 28: 575–577
Lang A, Geissler HE, Mutschler E (1979) Bestim-mung und Vergleich der Plasma-und Urinkonzentrationen nach Gabe von (+)- und Tranylcypromin. Drug Res 9: 154–157
Mallinger AG, Edwards DJ, Himmelhoch JM, Knopf S, Ehler J (1986) Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. Clin Pharmacol Ther 40: 444 450
Malnoe A, Strolin-Benedetti M (1979) Metabolic fate of 3-(3-methylphenyl)-5-hydroxymethyl2-oxazolidinone (toloxatone), a new antidepressant agent, in man. Xenobiotica 9: 281–288
Morikawa F, Ueda T, Arai Y, Kinemuchi H (1986) Inhibition of monoamine oxidase A-form and semicarbazide-sensitive amine oxidase by selective and reversible monoamine oxidase-A inhibitors, amiflamine and FLA 788 (+). Pharmacology 32: 38–45
Morrison JA (1965) The absorption, excretion and metabolic fate of mephenoxalone in the dog. Arch Int Pharmacodyn 157: 385–399
Mutschler M, MÖhrke W (1983) Kinetics of MAO inhibitors. Mod Probl Pharmacopsychiatry 19: 126–134
Poirier MF, Olie JP, Lôo H, Deniker P, Strolinbenedetti M, Rovei V, Lesage A (1983) Antidepressive activity, pharmacokinetics and biochemical properties of cimoxatone, a new reversible MAO-A inhibitor. Encephale 9: 331–343
Pons G, Schoerlin MP, Tam YK, Doran C, Pfefen JP, Francoual Ch, Pedarriosse AM, Chavinie J, Olive G (1990) Moclobemide excretion in human breast milk. Br J Clin Pharmacol 29: 27–31
Raaflaub J, Haefelfinger P, Trautmann KH (1984) Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. Drug Res 34: 80–82
Reynolds GP, Riederer P (1981) Tranylcypromine isomers in the treatment of Parkinson’s disease. Int Pharmacopsychiatry 16: 30–33
Riederer P, Reynolds GP, Youdim MBH (1981) Selectivity of MAO inhibitors in human brain and their clinical consequences. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors–the state of the art. Wiley, London, pp 63–76
Robinson DS, Mes A, Cooper TB (1980) Relationships of plasma phenelzine levels to platelet MAO inhibition, acetylator phenotype, and clinical outcome in depressed outpatients. Clin Pharmacol Ther 27: 280
Robinson DS, Cooper TB, Jindal SP, Corcella J, Lutz T (1985) Metabolism and pharmacokinetics of phenelzine: lack of evidence for acetylation pathway in humans. J Clin Psychopharmacol 5: 333–337
Rovei V, Rumigny JF (1985) Biochimie, pharmacocinétique et biotransformation de la toloxatone (Humoryl®), un nouvel inhibiteur reversible de la MAO-A. Extraits du Compte Rendu du Congres de Psychiatrie et de Neurologie de Langue Française. LXXXIII Session Besançon, pp 333–343
Rovei V, Chanoine F, Strolin-Benedetti M, Zini R, Tillement JP (1983) Plasma protein binding of the reversible type A MAO inhibitor cimoxatone. Biochem Pharmacol 32: 2303–2308
Rovei V, Mitchard M, Strolin-Benedetti M, Ken-Dall MJ (1984a) Pharmacokinetic and relative bioavailability studies of cimoxatone in humans. Int J Clin Pharmacol Ther Toxicol 12: 56–62
Rovei V, Mitchard M, Strolin-Benedetti M (1984b) Pharmacokinetics and metabolism of cimoxatone in rat, dog and man. In:Tipton KF (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, New York, pp 173–184
Rovei V, Vajta S, LE Moing JP, Strolin-Benedetti M (1984c) Metabolism of toloxatone in man. In: Tipton KF et al. (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, New York, pp 633–634
Schoerlin MP, DA Prada M (1990) Species-specific biotransformation of moclobemide: a comparative study in rats and humans. Acta Psychiatr Scand [Suppl 3631: 108–110
Schoerlin MP, Mayersohn M, Kom A, Eggers H (1987) Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor. Single and multiple dosing in normal subjects. Clin Pharmacol Ther 42: 395–404
Schoerlin MP, Horber F, Frey F, Mayersohn M (1990) Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. J Clin Pharmacol 30: 272–284
Schneider W, Keller B, Degen PN (1989) Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection. J Chromatogr 488: 275–282
Stephanis CN, Alevizos BH, Papadimitriou GN (1982) Antidepressant effect of Ro 11–1163, a new MAO inhibitor. Int Pharmacopsychiatry 17: 43–48
Stoeckel K, Pfefen JP, Mayersohn M, Schoerlin MP, Andressen C, Ohnhaus EE, Frey F, Guentert TW (1990) Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand [Suppl 3601: 94–97
Strolin-Benedetti M, Keane PE (1980) Metabolism in man of MD 780515, a new reversible type A monoamine oxidase (MAO) inhibitor. I World Conference on Clinical Pharmacology and Therapeutics, London (Abstract 190 )
Strolin-Benedetti M, Rovei V, Dencker SJ, Nagy A, Johansson R (1982) Pharmacokinetics of toloxatone in man following intravenous and oral administrations. Drug Res 32: 276–280
Strolin-Benedetti M, Boucher T, Fowler CJ (1983) The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition, by cimoxatone, toloxatone and MD 770–222. Naunyn Schmiedebergs Arch Pharmacol 323: 315–320
Waldmeier PC, Baumann PA, Delini-Stula A, Be-Masconi R, Sigg K, Buech O, Felner AE (1983) Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase. Mod Probl Pharmacopsychiatry 19: 31–52
Waldmeier F, Czendlik C, Faigle JW, Moppert J (1988) Disposition and biotransfommation of the MAO-A inhibitor trial drug brofaromine in healthy male volunteers. European Drug Metabolism Workshop, Konstanz
Youdim MBH, Aronson JK, Blau K, Green AR, grahame-Smith DG (1979) Tranylcypromine („Parnate“) overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med 9: 377–382
Yu PH, Davis BA, Durden DA (1991) Enymatic Nmethylation of phenelzine catalyzed by methyltransferases from adrenal and other tissues. Drug Metab Disposl9: 830–834
Akindele MO, Evans JI, Oswald I (1970) Mono amine oxidase inhibitors, sleep and mood. Electroencephalogr Clin Neurophysiol 29: 47–56
Baker GB, Hiob LE, Dewhurst WG (1980) Effects of monoamine oxidase inhibitors on release of dopamine and 5-hydroxytryptamine from rat striatum in vitro. Cell Mol Biol 26: 182–186
Bieck PR, Antonin K-H, Galon R, Oxenkrug G (1988) Effect of brofaromine and pargyline on human plasma melatonin concentrations. Prog Neuropsychopharmacol Biol Psychiatry 12: 93–101
Bieck PR, MÜhlbauer B, antonin KH (1989) Differential effects of brofaromine and moclobemide on melatonin secretion. In: Stefanis CN, Soldatos CR, Rabavilas AD (eds) Psychiatry today. Accomplishments and promises (Proc VIII World Congr Psychiatry, Athens 1989). Excerpta Medica International Congress Series 899 (Abstr No 1946 )
Burkard WP, Bone rn EP, DA Prada M, Martin JR, POLC P, Schaffner R, Scherschlicht R, Hefti F, MÜller Rkm, Wyss P-C, Haefely W (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248: 391–399
Cohen RM, Pickar D, Garnett D, Lipper S, Gillin JC, Murphy DL(1982) REM sleep suppression induced by selective monoamine oxidase inhibitors. Psychopharmacology 78: 137–140
DA Prada M, Kettler R, Burkard WP, Haefely WE (1984) Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain cate- cholamines and tyramine pressor effects in rats. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic Press, London, pp 137–154
DA Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248: 400–414
Delini-Stula A, Radeke E, Waldmeier PC (1988) Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. In: Casey DE, Christensen AV(eds) Psychopharmacology: current trends. Springer, Berlin Heidelberg New York Tokyo, pp 147–158
Dyck LE, Dewar KM (1986) Inhibition of aromatic L-amino acid decarboxylase and tyrosine aminotransferase by the monoamine oxidase inhibitor phenelzine. J Neurochem 46: 1899–1903
Hendley ED, Snyder SH (1968) Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant activity. Nature 220: 1330–1331
Jouvet M (1967) Neurophysiology of the states of sleep. Physiol Rev 47: 117–177
Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykko K, Vuorinen J, Zimmer RH (1989) Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 27: 243–255
Lyles GA(1984) The interaction of semicarbazide-sensitive amine oxidase with MAO inhibi-tors. In: Tipton KF, Dostert P, Strolin Benedetti M(eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp 547–556
Maxwell RA, White HL (1978) Tricyclic and monoamine oxidase inhibitor antidepressants: structure-activity relationships. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol 14. Plenum Press, New York, pp 83–155
Meltzer HY, Fang VS, Tricou BJ, Robertson A (1982) Effects of antidepressants on neuroen- docrine axis in humans. In: Costa E, Racagni G (eds) Typical and atypical antidepressants: clinical practice. Raven Press, New York, pp 303–316
Mendlewicz J, Youdim MBH (1977) Monoamine oxidase inhibitors and prolactin secretion. Lancet ii: 507
Monti JM (1989) Effect of a reversible monoamine oxidase-A inhibitor (moclobemide) on sleep of depressed patients. Br J Psychiatry 155 [Suppl 6]: 61–65
Murphy DL, Garrick NA, Tamarkin L, Taylor PL, Markey SP (1986) Effects of antidepressants and other psychotropic drugs on melatonin release and pineal gland function. J Neural Transm [Suppl] 21: 291–309
Nassar BA, Huang Y-S, Mcdonald AT, Jenkins KD, Horrobin DF (1988) The influence of phenelzine and tranylcypromine on the release of prostaglandins from the rat mesenteric vascular bed. Can J Physiol Pharmacol 66: 1206–1209
Nolen WA, Haffmans J, Jansen GS (1988) Brofaromine and tranylcypromine in resistant depression. Psychopharmacology 96 [Suppll: 280
Oniani TN, Akhvlediani GR (1988) Influence of some monoamine oxidase inhibitors on the sleep-wakefulness cycle of the cat. Neurosci Behav Physiol 18: 301–306
Ortmann R, Waldmeier PC, Radecke E, Felner A, Delini-Stula A (1980) The effects of 5-HT uptake-and MAO-inhibitors on L-5-HTP-induced excitation in rats. Naunyn Schmiedebergs Arch Pharmacol 311: 185–192
Ortmann R, Schaub M, Felner A, Lauber J, Christen P, Waldmeier PC (1984) Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 84: 22–27
Oxenkrug GF, Mclntyre IM, Jain AK, Balon R, Appel D, Mccauley RB (1986) Single dose of tranylcypromine increases human plasma melatonin. Biol Psychiatry 21: 1085–1089
Perenyi A, Bagdy G, Arato M (1983) An early phase II trial with L-Deprenyl for the treatment of neuroleptic-induced parkinsonism. Pharmacopsychiatry 16: 143–146
Porsolt RD (1981) Behavioral despair. In: Enna SJ, Malick JB, Richelson E (eds) Antidepressants: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 121–139
Scheinin M, Koulu M, Vakkuri O, Vuorinen J, Zim-Mer RH (1990) Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans. Prog Neu- ropsychopharmacol Biol Psychiatry 14: 73–82
Scherschlicht R, POLC P, Schneeberger J, Steiner M, Haefely W (1982) Selective suppression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants. In: Costa E, Racagni G (eds) Typical and atypical antidepressants: molecular mechanisms. Raven Press, New York, pp 359–364 (Adv Biochem Psychopharmacol, vol 31 )
Stefanis CN, Alevizos B, Markianos M, hatzima-Nolis J (1988) Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings). J Neural Transm [Suppl] 26: 87–95
Steiger A, Holsboer F, Gerken A, Demisch L, Benkert O (1987a) Results of an open clinical trial of brofaromine (CGP 11305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression. Pharmacopsychiatry 20: 262–269
Steiger A, Holsboer F, Benkert O (1987b) Effects of brofaremine (CGP 11305 A), a short-acting, reversible, and selective inhibitor of MAO-A on sleep, nocturnal penile tumescence and nocturnal hormone secretion in three healthy volunteers. Psychopharmacology 92: 110–114
Tuomisto J, Smith DF (1986) Effects of tranylcypromine enantiomers on monoamine uptake and release and imipramine binding. J Neural Transm 65: 135–145
Waldmeier PC, STÖcklin K (1989) The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo. Eur J Pharmacol 169: 197–204
Waldmeier PC, Baumann PA, Delini-Stula A, Bernasconi R, Sigg K, Buech O, Felner AE (1983) Characterization of a new, reversible and short-acting inhibitor of type A monoamine oxidase. In: Beckmann H, Riederer P (eds) Monoamine oxidase and its selective inhibitors: new concepts in therapy and research. Karger, Basel, pp 31–52 (Mod Probl Pharmacopsychiatry, vol 19 )
Wyatt RJ, Fram DH, Kupfer DJ, Snyder F (1971) Total prolonged drug-induced REM sleep suppression in anxious-depressed patients. Arch Gen Psychiatry 24: 145–155
Youdim MBH, Finberg JPM, Tipton KF(1988) Monamine oxidase. In: Trendelenburg Ü, Weiner N (eds) Catecholamines I. Springer, Berlin Heidelberg New York Tokyo, pp 119192 (Handb Exp Pharmacol, vol 90/1)
Anderson MC, Waldmeier PC, Tipton KF(1991) The inhibition of monoamine oxidase by brofaromine. Biochem Pharmacol 41: 1871–1877
Arai Y, Kimura H, Maeda T (1986) Topographic atlas of monoamine oxidase-containing neurons in the rat brain studied by an improved histochemical method. Neuroscience 19: 905–925
Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan S-W, Seeburg PH, Shih JC
cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85: 4934–4938
Blackwell B, Marley E, Price J, Taylor D (1967) Hypertensive interactions between monoamine oxidase inhibitors and food stuffs. Br J Psychiatry 113: 349–365
Buffoni F, Tipton KF (eds) (1988) 3rd Amine Oxidases International Workshop, Firenze, Italy, September 1–3, 1988. Pharmacol Res Commun 20 [Suppl 4]
Burrows GD, DA Prada M(eds) (1989) Reversible MAO-A inhibitors as antidepressants–basic advances and clinical perspectives. J Neural Transm 28 [Suppl]
Cesura AM, Muggli-Maniglio D, Lang G, Imhof R, DA Prada M (1990) Monoamine oxidase inhibition by moclobemide and 2-amino-ethyl carboxamide derivatives: mode of action and kinetic characteristics. J Neural Transm [Suppl] 32: 165–170
Colzi A, D’agostini F, Kettler R, Borroni E, DA Prada M (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm [Suppl] 32: 79–84
DA Prada M, Kettler R, Keller HH, Burkard WP (1988a) Ro 19–6327, a reversible, highly selective inhibitor of type B monoamine oxidase, completely devoid of tyramine potentiating effects: comparison with selegiline. In: Sandler M et al. (eds) Progress in catecholamine research, part B. Central aspects. Alan R Liss, New York, pp 9–363
DA Prada M, Kettler R, ZÜrcher G, Keller HH (1988b) Hemmer der MAO-B und COMT: Möglichkeiten ihrer Anwendung bei der Parkinson-Therapie aus heutiger Sicht. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der Parkinson-Therapie (6. Frankfurter Parkin-son-Symposium, 26–27 Feb 1988 ). Editiones Roche, Basel, S 309–322
DA Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248: 400–1414
DA Prada M, Kettler R, Burkard WP, Lorez HP, Haefely W (1990a) Some basic aspects of reversible inhibitors of MAO-A (RIMA). Acta Psychiatr Scand 82 [Suppl 360]: 7–12
DA Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss P-C, Kyburz E, Imhof R (1990b) From moclobemide to Ro 19–6327 and Ro 41–1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm 29 [Suppl]: 279–292
Delini-Stula A, Radeke E, Waldmeier PC (1988) Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. Psychopharmacol Ser 1988: 145–158
Eisen’ Iofer G, Goldstein DS, Ropchak TG, Nguyen HQ, Keiser HR, Kopin HJ (1988) Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J Auton Nerv Syst 24: 1–14
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297
Kettler R, Cesura AM, Dingemanse J, DA Prada M (1990) MAO-B inhibition in rabbit tissues and in human platelets by Ro 19–6327 shows similar time-course. J Neural Transm [Suppl] 32: 211–214
Konrad C, Svoma E, Jellinger K, Riederer P, Denney P, Thibault J (1988) Topographic immunocytochemical mapping of MAO-A, MAO-B and tyrosine hydroxylase in human post mortem brain stem. Neuroscience 26: 791–802
Konradi C, Kornhuber J, Froelich L, Fritze J, Heinsen H, Beckmann H, Schulz E, Riederer P (1989) Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 33: 383–400
Laux G, Riederer P (Hrsg) (1989) Neue selektive Monoamine Oxidase Hemmer in der Therapie depressiver Erkrankungen. Psychiatr Praxis 16 (Sonderheft 1): 1–50
Pare CMB (1985) The present status of monoamine oxidase inhibitors. Br J Psychiatry 146: 576–584
Paech C, Salach JI, Singer TP (1980) Suicide inactivation of monoamine oxidase by transphenylcyclopropylamine. J Biol Chem 255: 2700–2704
Price GW, Bench CJ, Cremer JC, Luthra SK, Turton DR, Lammertsma AA, Kettler R, DA Prada M, Wood N, Jamieson K, Mcclelland G, Frackowiak RSJ (1990) Inhibition of brain monoamine oxidase-B by Ro 19–6327 — in vivo measurement using positron emission tomography. Eur J Pharmacol 183: 166
Priest RG(eds) (1989) Depression and reversible monoamine oxidase inhibitors — new perspectives. Br J Psychiatry 155 [Suppl 6]
Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with L-deprenyl. J Neurochem 46: 1359–1365
Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52: 515–520
Saura Marti J, Kettler R, DA Prada M, Richards JG (1990) Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm [Suppl] 32: 4953
Saura J, Kettler R, DA Prada M, Richards JG (1992) Quantitative enzyme radioautography with [3H]Ro 41–1049 and [3H1 Ro 19–6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs and human brain. J Neurosci 12: 1977–1999
Singer TP, Husain M (1982) Monoamine oxidase and its reaction with suicide substrates. In: Massay V, Williams CH (eds) Flavins and fla- voproteins. Elsevier, Amsterdam, pp 389–401
Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM, Weingartner H, Mueller EA, Murphy DL (1987) L-Deprenyl in Alzheimer’s disease. Arch Gen Psychiatry 44: 427–433
Thorpe LW, Westlund KN, Kochersperger LM, Abell CW, Denney M (1987) Immunocytochemical localization of monoamine oxidase A and B in human peripheral tissues and brain. J Histochem Cytochem 35: 23–32
Waldmeier PC (1987) Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). J Neural Transm [Suppl] 23: 55–72
Waldmeier PC, Delini-Stula A, MaÎtre l (1976) Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn Schmiedebergs Arch Pharmacol 292: 9–14
Waldmeier PC, Feldtrauer J-J, Stoecklin K, Paui. E (1983) Reversibility of the interaction of CGP 11 305A with MAO in vivo. Eur J Pharmacol 94: 101–108
Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230: 181–183
Westlund KN, Denney RM, Rose RM, Abell CW (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25: 439–456
Weyler W, Hsu Y-PP, Braekefield XO (1990) Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47: 391–417
Youdim MBH, Finberg JPM (1991) New directions in monoamine A and B selective inhibitors and substrates. Biochem Pharmacol 41: 155–162
Youdim MBH, DA Prada M, Amrein R (eds) (1988a) The cheese effect and new reversible MAO-A inhibitors. J Neural Transm [Suppl] 26
Youdim MBH, Finberg JPM, Tipton KF (1988b) Monoamine oxidase. In: Trendelenburg U, Weiner N (eds) Catecholamines I. Springer, Berlin Heidelberg New York Tokyo, pp 119–192 (Handbook Exp Pharmacol, vol 90/I)
Amsterdam JD, Berwish NJ (1989) High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 22: 21–25
Angst J (1990) Use of reversible inhibitors of monoamine oxidase-A in major depression and other psychiatric disorders. The treatment of depression in the 1990s–a focus on moclobemide. Acta Psychiatr Scand [Suppl 360] 82: 1–110
Angst J, Stabl M(1992) Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 106 [Suppl]: S 109–5113
Atkinson RM, Ditman KS (1965) Tranylcypromine: a review. Clin Pharmacol Ther 6: 631–655
Bartholomew AA (1962) An evaluation of tranylcypromine (Parnate) in the treatment of depression. Med J Aust 49: 655 - -662
Beckmann H, Laux G (1991) Aktuelles zur Therapie mit MAO-Hemmern. Krankenhauspsychiatrie 2: 201–202
British Medical Research Council (1965) Clinical trial of the treatment of depressive illness. Br Med J 1: 881–886
Bucci L (1971) The dyskinesias: a new therapeutic approach. Dis Nerv Syst 32: 324–327
Chan-Palay V (1992) Depression and senile dementia of the Alzheimer type: a role for modobemide. Psychopharmacology [Suppl] 106: S137 - S139
COOPER AJ, O’REILLY RL (1991) Update on the monoamine oxidase inhibitors ( MAOIs ). Today’s Therapeutic Trends 9: 35–54
Crane Ge (1957) Iproniazid (Marsilid) phosphate: a therapeutic agent for mental disorders and debilitating diseases. Psychiatr Res Rep Am Psychiatr Assoc 8: 142–152
Danish Univ Antidepressant Group (1993) J Affect Disord 28: 105–116
Davidson JRT, Pelton S (1986) Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 17: 87–95
Davidson JRT, Miller RD, Turnbull CD, Sullivan JL (1982) Atypical depression. Arch Gen Psychiatry 39: 527–534
Davidson JRT, Giller EL, Zisook S, Helms MJ (1991) Predictors of response to monoamine oxidase inhibitors: do they exist? Eur Arch Psychiatry Clin Neurosci 241: 181–186
Davis JM, Glassman AH (1989) Antidepressant drugs. In: Kaplan HI, Sadock BJ (eds) Comprehensive textbook of psychiatry, vol 2, 5th ed. Williams and Wilkins, Baltimore Hong Kong London Sydney, pp 1627–1655
Dowson JH (1987) MAO inhibitors in mental disease: their current status. J Neural Transm 23 [Suppl]: 121–138
English DC (1961) A comparative study of antidepressants in balanced therapy. Am J Psychiatry 117: 865–872
Fitton A, Faulds D, Goa KL (1992) Moclobemide. A review of its pharmacological properties and therapeutic use’ in depressive illness. Drugs 43: 561–596
Freyhanfa(1960) The modern treatment of depressive disorders. Am J Psychiatry 116: 1057–1064
Georgotas A, Friedman E, Mccarthy M, Mann J, Krakowski M, Siegel R, Ferris S (1983) Resi-stant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry 18: 195–205
Glick BS (1964) Double-blind study of tranylcypromine and phenelzine in depression. Dis Nerv Syst 25: 617–619
Gottfries CG (1963) Clinical trial with the monoamine oxidase inhibitor tranylcypromine on a psychiatric clientele. Acta Psychiatr Scand 39: 463–472
Himmelhoch JM, Fuchs CZ, Symons BJ (1982) A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 170: 628–634
Himmelhoch JM, Thase ME, Mallinger AG, Houck P (1991) Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148: 910–916
Howland RH (1991) Pharmacotherapy of dysthymia: a review. J Clin Psychopharmacol 11: 83–92
Hutchinson JT, Smedberg D (1963) Treatment of depression: a comparative study of E.C.T. and six drugs. Br J Psychiatry 109: 536–538
Jenike MA (1984) A case report of successful treatment of dysmorphophobia with tranylcypromine. Am J Psychiatry 141: 1463–1464
Jenike MA, Surman OS, Gassem NH et al. (1983) Monoamine oxidase inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 44: 131–132
Kelly D, Guiguis W, Frommer E et al. (1970) Treatment of phobic states with antidepressants: a retrospective study of 246 patients. Br J Psychiatry 116: 387–398
Khanna JL, Pratt S, Burdizk EG, Chaddha RL (1963) A study of certain effects of tranylcypromine, a new antidepressant. J New Drugs 3: 227–232
Kline NS (1958) Clinical experience with iproniazid (Marsilid). J Clin Exp Psychopathol [Suppl 1] 19: 72–79
Laux G (1993a) Do MAO-B-inhibitors have any role in the treatment of depression? In: Szelenyi I Inhibitors of monoamine oxidase B. Birkhäuser, Basel Boston, pp 319–326
Laux G (1993b) Kontrollierte Vergleichsstudien mit Moclobemid in der Depressionsbehandlung. Eine Übersicht. Minch Med Wochenschr (im Druck )
Laux G (1993c) Einsatzmöglichkeiten der MAO-Hemmer bei Angst-und Panikerkrankungen. In: Moller HJ, Kasper S (Hrsg) Diagnostik und Therapie von Angst-und Panikerkrankungen. SMV, Gräfelfing
Laux G, Riederer P (Hrsg) (1989) Neue selektive Monoaminoxidase-Hemmer in der Therapie depressiver Erkrankungen. Psychiat Prax 16 (Sonderheft): 1–50
Lerer B, Bleich A, Kotler M, Garb R, Hertzberg M, Levin B (1987) Posttraumatic stress disorder in Israeli combat veterans. Arch Gen Psychiatry 44: 976–981
Lesse S (1962) Relative merits of tranylcypromine alone and tranylcypromine in combination with trifluoperazine in the treatment of patients with severe agitated depressions. Am J Psychiatry 118: 934–935
Liebowitz MR, Klein DF (1979) Hysteroid dyspho- ria. Psychiatr Clin North Am 2: 555–575
Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A (1986) Phenelzine in social phobia. J Clin Psychopharmacol 6: 93–98
Liebowitz MR, Quitkin FM, Stewart JW, Mcgrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF (1988) Antidepressant specificity in atypical depression. Arch Gen Psychiatry 45: 129–137
Lydiard RB, Ballenger JC (1987) Antidepressants in panic disorder and agoraphobia. J Affect Disord 13: 153–168
Mcgrath PJ, Stewart JW, Harrison W, Quitkin FM (1987) Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 23: 169–172
MÖller HJ, Volz HP (1992) Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year. J Affect Disord 26: 163–172
MÖller HJ, Wendt G, Waldmeier P (1991) Brofaromine — a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings. Pharmacopsychiatry 24: 50–54
Murphy DL, Aulakh CS, Garrick NA, Sunderland T (1987) Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 545–552
Nanda RN, Johnson RH, Keogh HJ (1976) Treatment of neurogenic orthostatic hypotension with a monoamine oxidase inhibitor and tyramine. Lancet ii: 1164–1167
Nies A, Robinson DS(1982) Monoamine oxidase inhibitors. In: Paykel ES (ed) Handbook of affective disorders. Churchill Livingstone, Edinburgh London Melbourne New York, pp 246–261
Nolen WA(1986) Tranylcypromine in depression resistant to cyclic antidepressants. Clin Neuropharmacol 9 [Suppl 4]: 569–571
Pare CMB (1985) The present status of monoamine oxidase inhibitors. Br J Psychiatry 146: 576–584
Polier WZ, Rudorfer MV, Manji H (1991) The pharmacologie treatment of depression. N Engl J Med 325: 633–642
Priest RG (1989) Depression and reversible monoamine oxidase inhibitors — new perspectives. Br J Psychiatry [Suppl 61: 1–88
Quitkin F, Rifkin A, Klein DF (1979) Monoamine oxidase inhibitors. Arch Gen Psychiatry 36: 749–760
Quitkin FM, Harrison W, Stewart JW, Mcgrath PJ, Tricamo E, Ocepek-Welikson K, Rabkin JG, Wagner SG, Nunes E, Klein DF (1991) Response to phenelzine and imipramine in placebo nonresponders with atypical depression. Arch Gen Psychiatry 48: 319–323
Ravaris CL, Robinson DL, Ives JO, Nies A, Bartlett D (1980) Phenelzine and amitriptyline in the treatment of depression. Arch Gen Psychiatry 37: 1075–1080
Razani J, White Kl, White J, Simpson G, Sloane RB, Rebel R, Bulmer R (1983) The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry 40: 657–661
Richmond PW, Roberts AH (1964) A comparative trial of imipramine, amitriptyline, isocarboxazid and tranylcypromine in out-patient depressive illness. Br J Psychiatry 110: 846–850
Robinson DS, Nies A, Ravaris CL, Lamborn KR (1973) The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. Arch Gen Psychiatry 29: 407–413
Robinson DS, Nies A, Ravaris CL, Ives JO, Bartlett D (1978) Clinical pharmacology of phenelzine. Arch Gen Psychiatry 35: 629–635
Rom M (1959) The phobic anxiety-depersonalization syndrome. Proc R Soc Med 52: 587–595
Schmauss M, Erfurth A (1989) Indikationen für eine Therapie mit MAO-Hemmern. Psychiat Prax 16 (Sonderheft): 2–6
Sheehan DV, Ballenger J, Jacobsen G (1980) Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 37: 51–59
Silberberg D, Armstrong R (1965) Tranylcypromine in multiple sclerosis. Lancet ii: 852–853
Spear FG, Hall P, Stirland JD (1964) A comparison of subjective responses to imipramine and tranylcypromine. Br J Psychiatry 110: 53–55
Thase ME, Carpenter L, Kupfer DJ, Frank E (1991) Atypical depression: diagnostic and pharmacologic controversies. Psychopharmacol Bull 27: 17–22
Thase ME, Mallinger AG, Mcknight D, Himmel-Hoch JM (1992) Treatment of imipramine-resistant recurrent depression. IV. A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 149: 195–198
Tiller JWG(1992) Post-stroke depression. Psy- chopharmacology 106 [Suppl]: S130 — S133
Trott GE, Friese HJ, Menzel M, Nissen G (1992) Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 106 [Suppll: S134 — S136
Tyrer P (1976) Towards rational therapy with monoamine oxidase inhibitors. Br J Psychiatry 128: 354–360
Tyrer P, Shawcross C (1988) Monoamine oxidase inhibitors in anxiety disorders. J Psychiat Res 22 [Suppl 11: 87–98
Tyrer P, Gardner M, Lambourn J, Whitford M (1980) Clinical and pharmacokinetic factors affecting response to phenelzine. Br J Psychiatry 136: 359–365
Tyrer P, Casey P, Gall J (1983) Relationship between neurosis and personality disorder. Br J Psychiatry 142: 404–408
West ED, Dally PJ (1959) Effect of iproniazid in depressive syndromes. Br Med J 1: 1491–1494
Wetzel J, Benkert O (1991) Moclobemid, ein reversibler Inhibitor der Monoaminoxidase A ( RIMA ). Fundam Psychiat 5: 76–85
White K, Pistole T, Boyd JL (1980) Combined MAOI-TCA vs. single antidepressant treatment: a pilot study. Am J Psychiatry 137: 1422–1425
White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, Sloane RB (1984) Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial. Psychopharmacology 82: 258–262
Amsterdam JD, Berwish NJ (1989) High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 22: 21–25
Atkinson RM, Ditman KS (1965) Tranylcypromine: a review. Clin Pharmacol Ther 6: 631–655
Beckmann H, Laux G (1991) Aktuelles zur Therapie mit MAO-Hemmern. Krankenhauspsychiatrie 2: 201–202
Carl G, Laux G (1989) Moclobemid in der Langzeitbehandlung Depressiver. Psychiat Prax 16 (Sonderheft): 48–50
Firron A, Faulds D, Goa KL (1992) Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43: 561–596
Guze BH, Baxter LR, Rego J (1987) Refractory depression treated with high doses of a monoamine oxidase inhibitor. J Clin Psychiatry 48: 31–32
Laux G (1993) Do MAO-B-inhibitors have any role in the treatment of depression? In: SzELENYI I (ed) Inhibitors of monoamine oxidase B. Birkhäuser, Basel Boston, pp 319–326
Murphy DL, Aulakh CS, Garrick NA, Sunderland T (1987) Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY(ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 545–552
Quitkin F, Rifkin A, Klein DF (1979) Monoamine oxidase inhibitors. Arch Gen Psychiatry 36: 749–760
Schmauss M, Erfurth A (1989) Indikationen für eine Therapie mit MAO-Hemmern. Psychiat Prax 16 (Sonderheft): 2–6
Tyrer P, Shawcross C (1988) Monoamine oxidase inhibitors in anxiety disorders. J Psychiat Res 22 [Suppl 1]: 87–98
Amsterdam JD, Berwish NJ (1989) High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 22: 21–25
Askenasy JJM, Yahr MD (1988) Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated? J Neural Transm 72: 67–76
Bakish D, Bradwejn J, Nair N, Mcclure J, Remick RA, Bulger L (1992) A comparison of modobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psycho-pharmacology 106 [Suppl]: S98 — S101
Beckmann H, Laux G (1991) Aktuelles zur Therapie mit MAO-Hemmern. Krankenhauspsychiatrie 2: 201–202
Blackwell B (1981) Adverse effects of antidepressant drugs, part 1. Monoamine oxidase inhibitors and tricyclics. Drugs 21: 201–219
Blackwell B, Simon Js (1988) Antidepressant drugs. In: Dukes MNG, Beeley L (eds) Side effects of drugs, annual 12. Elsevier, Amsterdam, pp 8–25
Boakes AJ, Laurence DR, Teoh PC, Barar FSK, Benedikter LT, Prichard BNC (1973) Interactions between sympathomimetic amines and antidepressant agents in man. Br Med J 1: 311–315
Boulton AA, Maitre L, Bieck PR, Riederer P(eds) (1985) Neuropsychopharmacology of the trace amines. Humana, Clifton
Browne B, Linter S (1987) Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment. Br J Psychiatry 151: 210–212
Carl G, Laux G (1989) Moclobemid in der Langzeitbehandlung Depressiver. Psychiat Prax 16 (Sonderheft): 48–50
Cockhill LA, Remick RA (1987) Blood pressure effects of monoamine oxidase inhibitors — the highs and lows. Can J Psychiatry 32: 803–808
Cohen RM, Pickar D, Murphy DL (1980) Myoclonus-associated hypomania during MAO-inhibitor treatment. Am J Psychiatry 137: 105–106
Cooper AJ, Ashcroft G (1965) Modification of insulin and sulfonylurea hypoglycemia by monoamine oxidase inhibitor drugs. Diabetes 16: 272–274
Cordas TA, Neto FL (1991) Weight gain and MAO inhibitors: two case reports (letter). J Clin Psychopharmacol 11: 227–228
DA Prada M, Kettler R, Keller HH, Burkard WP, Haepely WE (1990) Präklinisches Profil der neuen reversiblen MAO-A-Inhibitoren Moclobemid und Brofaromin. Minch Med Wochenschr 132 [Suppl 11: 5–12
Davidson JRT (1992) Monoamine oxidase inhibitors. In: Paykel ES (ed) Handbook of affective disorders, 2nd ed. Churchill Livingstone, Edinburgh London Madrid Melbourne New York Tokyo, pp 345–358
Fallon B, Foots B, Walsh T, Roose SP (1988) „Spontaneous“ hypertensive episodes with monoamine oxidase inhibitors. J Clin Psychiatry 49: 163–165
Fier M (1991) Safer use of MAOIs (letter). Am J Psychiatry 148: 391
FrrrON A, FAULDS D, GOA KL (1992) Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43: 561–596
Guze BH, Baxter LR JR (1986) The serotonin syndrome: case responsive to propranolol (letter). J Clin Psychopharmacol 6: 119–120
Hetzel W (1992) Safety of moclobemide taken in overdose for attempted suicide. Psychopharmacology 106 [Suppl]: S127 — S129
Jenike MA (1984) The use of monoamine oxidase inhibitors in the treatment of elderly, depressed patients. J Am Geriatr Soc 32: 571–575
Joffe RT (1990) Afternoon fatigue and somnolence associated with tranylcypromine treatment. J Clin Psychiatry 51: 192–193
Kline NS, Cooper TB (1980) Monoamine oxidase inhibitors as antidepressants. In: Hoffmeister F, Stille G (eds) Psychotropic agents, part 1. Antipsychotics and antidepressants. Springer, Berlin Heidelberg New York
Laux G (1993) Kontrollierte Vergleichsstudien mit Moclobemid in der Depressionsbehandlung. Eine Übersicht. Munch Med Wochenschr (im Druck )
Laux G, Beckmann H, Classen W, Becker T (1989) Moclobemide and maprotiline in the treat-ment of inpatients with major depressive disorder. J Neural Transm 28 [Suppl]: 45–52
Lieberman JA, Kane JM, Reife R (1985) Neuromuscular effects of monoamine oxidase inhibitors. J Clin Psychopharmacol 5: 221–228
Lloyd JTA, Walker DRH (1965) Death after combined dexamphetamine and phenelzine. Br Med J 2: 168–169
Marley E, Wozniak KM (1984) Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res 18: 191–203
Matter BJ, Donat PE, Brill ML, Ginn HE (1965) Tranylcypromine sulfate poisoning. Successful treatment by hemodialysis. Arch Intern Med 116: 18–20
Mattsson A, Seltzer RL (1981) MAOI-induced rapid cycling bipolar affective disorder in an adolescent. Am J Psychiatry 138: 677–679
Nies A (1983) Clinical applications of MAOIs. In: Barrows GD, Norman TR, Davies B (eds) Antidepressants. Elsevier, Amsterdam, pp 229–247
Nies A (1984) Differential response patterns to MAO inhibitors and tricyclics. J Clin Psychiatry 45: 70–77
Nies A, Robinson DS (1982) Monoamine oxidase inhibitors. In: Paykel ES (ed) Handbook of affective disorders. Churchill Livingstone, Edinburgh London Melbourne New York, pp 246–261
Pare CMB (1985) The present status of monoamine oxidase inhibitors. Br J Psychiatry 146: 576–584
Peterson JC, Pollack RW, Mahoney JJ, Fuller TJ (1978) Inappropriate antidiuretic hormone secondary to a monoamine oxidase inhibitor. J Am Med Assoc 239: 1422–1423
Physicians’ Desk Reference (1991) Publisher Barnhart ER, Medical Economics Data, Oradell, NJ
Pope HG, Jonas JM, Hudson JL, Kafka MP (1985) Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. Am J Psychiatry 142: 491–492
Rabkin J, Quitkin FM, Harrison W, Tricamo E, Mcgrath P (1984) Adverse reactions to monoamine oxidase inhibitors. A comparative study. J Clin Pharmacol 4: 270–278
Razani J, White KL, White J, Simpson G, Sloane RB, Rebel R, Bilmer R (1983) The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry 40: 657–661
Remick RA, Froese C, Keller FD (1989) Common side effects associated with monoamine oxi- dase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 13: 497–504
Richards GA, Fritz VU, Pincus P, reyneke J (1987) Unusual drug interactions between monoamine oxidase inhibitors and tricyclic antidepressants. J Neurol Neurosurg Psychiatry 50: 1240–1241
Rudorfer MV (1992) Monoamine oxidase inhibitors: reversible and irreversible. Psychopharmacol Bull 28: 45–57
Schmauss M, Kapfhammer HP, Meyr P, Hoff P (1988) Combined MAO-inhibitor and tri-(tetra) cyclic antidepressant treatment in therapy resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 12: 523–532
Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148: 705–713
Teicher MH, Cohen BM, Baldessarini RJ, Cole JO (1988) Severe daytime somnolence in patients treated with an MAOI. Am J Psychiatry 145: 1552–1556
Tipton KF (1990) The design and behaviour of selective monoamine oxidase inhibitors. In: LEONARD BE, SPENCER P (eds) Antidepressants: thirty years on. CNS ( Clinical Neuroscience) Publishers, London, pp 195–203
Versiani M, Oggero U, Alterwain P, Capponi R, Dajas F, Heinze-Martin G, Marquez CA, Poleo MA, Rivero-Almanzor LE, Rossel L, Schmid-Burgk W, Ucha Udabe R (1989) A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry 155 [Suppl 6]: 72–77
Versiani M, Nardi AE, Figueira ILV, Stabl M (1990) Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand 82 [Suppl 3601: 24–28
Walker JI, Davidson J, Zung WWK (1984) Patient compliance with MAO inhibitor therapy. J Clin Psychiatry 45: 78–80
Watkins HC, Ellis CJK (1989) Ping Pong gaze in reversible coma due to overdose of monoamine oxidase inhibitor (letter). J Neurol Neurosurg Psychiatry 52: 539
White K, Pistole T, Bom Jl (1980) Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study. Am J Psychiatry 137: 1422–1425
White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G, Slonae RB (1984) Tranylcypromine vs nortriptyline vs placebo in depressed out-patients: a controlled trial. Psychopharmacology 82: 258–262
Youdim MBH, Aronson JK, Green AR, Grahamesmith DG (1979) Tranylcypromine („Parnate“) overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med 9: 377–382
Antonin KH, Jedrychowski M, Bieck PR (1990) Brofaromin. Pharmakodynamische und phar- makokinetische Untersuchungen an gesun- den Probanden mit einem neuen reversiblen Hemmstoff der MAO-A. Munch Med Wochenschr 132 [Stipp] 11: 13–17
Apa (American Psychiatric Association) (1990) The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging.
American Psychiatric Press, Washington DC AYD FH (1988) Tyramine in wine and beer. Int Drug Ther Newsletter 23: 37–40
Becker TH, Struck M, Laux G (1989) Depressionsbehandlung mit MAO-A-Inhibitoren: Offene Studie zur Direktumstellung von Moclobemid auf tri-/tetrazyklische Antidepressiva. Psychiat Prax 16: 447
Berlin I, Cournot A, Zimmer R, Pedarriosse A-M, Manfredi R, Molinier P, Puech AJ (1990) Evaluation and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects. Psycho-pharmacology 100: 40–45
Bieck PR, Antonin KH (1982) Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteers. Eur J Clin Pharmacol 22: 301–308
Bieck PR, Antonin K-H (1988) Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 8: 237–245
Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm [Suppl 281: 21–31
Bieck PR, Aichele G, Schick C, Hoffmann E, Nils-Son E (1988) Metabolism of tyramine in subjects treated with different monoamine oxidase inhibitors. In: Boulton AA, Juorio AV, downer RGH (eds) Trace amines: comparative and clinical neurobiology. Humana Press, Clifton, pp 423–437
Birkmayer W, Riederer P, Linauer W, Knoll J (1984) L-deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 59: 81–87
Blackwell B (1963) Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet ii: 849–851
Blackwell B (1981) Adverse effects of antidepressant drugs, part 1. Monoamine oxidase inhibitors and tricyclics. Drugs 21: 201–219
Blackwell B, Simon JS (1988a) Antidepressant drugs. In: DUKES MNG (ed) Myler’s side effects of drugs, 11 th ed. Elsevier, Amsterdam, pp 27–70
Blackwell B, Simon JS (1988b) Antidepressant drugs. In: Dukes MNG, Beeley L (eds) Side effects of drugs, anual 12. Elsevier, Amsterdam, pp 8–25
Blackwell B, Simon JS (1989) Antidepressant drugs. In: Dukes MNG, Beeley L (eds) Side effects of drugs, annual 13. Elsevier, Amsterdam, pp 6–16
Blackwell B, Marley E, Price J, Taylor D (1967) Hypertensive interactions between monoamine oxidase ( MAO) inhibitors and foodstuffs. Br J Psychiatry 113: 349–365
Browne B, Linter S (1987) Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implication of treatment. Br J Psychiatry 151: 210–212
Clary C, Schweizer E (1987) Treatment of MAOI hypertensive crisis with sublingual nifedipine. J Clin Psychiatry 48: 249–250
Cooper AJ (1989) Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry 155 [Suppl] 61: 38 - -45
DA Prada M, ZÜrcher G, WÜthrich I, Haefely WE (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm [Suppl] 261: 31–56
Devabhaktuni RV, Jampala VC (1987) Using street drugs while on MAOI therapy. J Clin Psychopharmacol 7: 60–61
Feiniserg M, DE Vigne J-P, Kronfol Z, Young E(1981) Duration of action of phenelzine in two patients. Am J Psychiatry 138: 379–380
Fraunfelder FT, Meyer SM (1987) Systemic re-actions to ophthalmic drug preparations. Med Toxicol 2: 287–293
Friend DT, Bell WR, Kline NS (1965) The action of L-dihydroxyphenylalanine in patients receiving nialamide. Clin Pharmacol Ther 6: 362–366
Gilburt SJA, Sutton JA, Hindmarch I (1991) The pharmacodynamics of brofaromine, alone and in combination with alcohol, in young healthy volunteers.Br J Clin Pharmacol 33: 245 P
Hannah P, Glover V, Sandler M(1988) Tyramine in wine and beer. Lancet is 879
Hansen JM, Christensen LK (1977) Drug interaction with oral sulphonylurea hypoglycaemic drugs. Drugs 13: 24–34
Kahn D, Silver JM, Opler LA (1989) The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors. J Clin Psychopharmacol 9: 198–202
Korn A, Eichler HG, Fischbach R, Gasic S (1986) Moclobemide, a new reversible MAO-inhibitor — interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology 88: 153–157
Marley E, Wozniak KM (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors. Psychol Med 13: 735 —749
Mendlewicz J, Youdim MBH (1978) Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO „type B“ inhibitor. J Neural Transm 43: 279–286
Murphy DL, Sunderland T, Cohen RM (1984) Monoamine oxidase-inhibiting antidepressants. Psychiatr Clin North Am 7: 549–562
Neil JF, Licata SM, May SJ, Himmelhoch JM (1979) Dietary non-compliance during treatment with tranylcypromine. J Clin Psychiatry 40: 33–37
Pare CMB (1985) The present status of monoamine oxidase inhibitors. Br J Psychiatry 146: 576–584
Pope HG, Jonas JM, Hudson JI, Kafka MP (1985) Toxic reaction to the combination of monoamine oxidase inhibitors and tryptophan. Am J Psychiatry 142: 491–492
Rabkin JG, Quitkin FM, Mcgrath P, Harrison W, Tricamo E (1985) Adverse reactions to monoamine oxidase inhibitors, part II. Treatment correlates and clinical management. J Clin Psychopharmacol 5: 2–9
Raskin A (1972) Adverse reaction to phenelzine: results of a nine-hospital depression study. J Clin Pharmacol 12: 22–25
Razani J, White KL, White J (1983) The safety and efficacy of combined amitriptyline and tranyl- cypromine antidepressant treatment: a con- trolled trial. Arch Gen Psychiatry 40: 657–661
Robinson DS, Kurtz NM (1987) Monoamine oxidase inhibiting drugs: pharmacologie and therapeutic issues. In: Meltzer HY (ed) Psycho-pharmacology: the third generation of progress. Raven Press, New York, pp 1297–1304
Schulz R, Bieck PR (1987) Oral tyramine pressor test and the safety of MAO inhibitor drugs. Psychopharmacology 91: 515–516
Sjoquist F (1965) Psychotropic drugs (2). Interaction between monoamine oxidase inhibitors (MAO) and other substances. Proc Roy Soc Med 58: 967–978
Smilkstein MJ, Smolinske SC, Rumack BH (1987) A case of MAO inhibitor/MDMA interaction: agony after ecstasy. Clin Toxicol 25: 149–159
Sullivan EA, Shulman KI (1984) Diet and monoamine oxidase inhibitors: a re-examination. Can J Psychiatry 29: 707–711
Tabakoff B, Lee JM, De Leon Jones F, Hoffman PL(1985) Ethanol inhibits the activity of the B form of monoamine oxidase in human platelet and brain tissue. Psychopharmacology 87: 152–156
Teychenne PF, Calne DB, Lewis PJ, Findley LJ (1975) Interactions of levodopa with inhibitors of monoamine oxidase and I-aromatic amino acid decarboxylase. Clin Pharmacol Ther 18: 273–277
Tiller JWG (1990) Antidepressants, alcohol and psychomotor performance. Acta Psychiatr Scand [Suppl 360]: 13–17
Tipton KF (1986) Enzymology of monoamine oxidase. Cell Biochem Funct 4: 79–87
Tolksdorf W, Baier D, Dingemanse J (1992) MO-noaminoxydase-Hemmstoffe und RIMA-Sub-stanzen in der Anästhesie. Anästh Intensivmed 33: 175–185
White K, Simpson G (1981) Combined MAOItricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol 1: 264–282
Angst J, Stabl M (1992) Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 106 [Suppll: 5109 — S113
Atkinson RM, Ditman KS (1965) Tranylcypromine: a review. Clin Pharmacol Ther 6: 631–655
Becker T, Struck M, Laux G (1989) Depressionsbehandlung mit MAO-A-Inhibitoren: Offene Studie zur Direktumstellung von Moclobemid auf tri-/tetrazyklische Antidepressiva. Psychiat Prax 16 (Sonderheft): 44–47
Ben-Arie O, George GCW (1979) A case of tranylcypromine ( Parnate) addiction. Br J Psychiatry 135: 273–274
Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm 28 [Suppl]: 21–31
Blackwell B (1976) Treatment adherence. Br J Psychiatry 129: 513–531
Brady KT, Lydiard RB, Kellner C(1991) Tranylcypromine abuse. Am J Psychiatry 148: 1268–1269
Briggs NC, Jefferson JW, Koenecke FH (1990) Tranylcypromine addiction: a case report and review. J Clin Psychiatry 51: 426–429
Carl G, Laux G (1989) Moclobemid in der Langzeitbehandlung Depressiver. Psychiat Prax 16 (Sonderheft): 48–50
Classen W, Laux G (1990) Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide. J Neural Transm [Suppl] 32: 185–188
Cohen BM, Baldessarini RJ (1985) Tolerance to therapeutic effects of antidepressants. Am J Psychiatry 142: 489–490
Cooper AJ, O’reilly RL (1991) Update on the monoamine oxidase inhibitors ( MAOIs ). Today’s Therapeutic Trends 9: 35–54
Cuthbert MF, Greenberg MP, Morley SW (1969) Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors. Br Med J 1: 404 406
DA Prada M, ZÜrcher G, WÜthrich I, Haefely WE (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm [Suppll 26: 31–56
Davidson J, Zung WWK, Walker JI (1984) Practi-cal aspects of MAO inhibitor therapy. J Clin Psychiatry 45: 81–84
DE Vanna M, Kummer J, Agnoli A, Gentili P, Lorizio A, Anand R (1990) Moclobemide compared with second-generation antidepressants in elderly people. Acta Psychiatr Scand 82 [Suppl 3601: 64–66
Dilsaver SC(1988) Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology. Acta Psychiatr Scand 78: 1–7
Elia J, Katz IR, Simpson GM (1987) Teratogenicity of psychotherapeutic medications. Psychopharmacol Bull 23: 531–586
Fier M (1991) Safer use of MAOIs. Am J Psychiatry 148: 391–392
Firron A, Faulds D, Goa KL (1992) Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43: 561–596
Frankel DA, Raskin DE (1985) Psychosis following phenelzine discontinuation. J Clin Psychopharmacol 5: 360
Georgotas A, Friedman E, Mccarthy M, Mann J, Krakowski M, Siegel R, Ferris S (1983) Re-sistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry 18: 195–205
Griffin N, Draper RJ, Webb MGT (1981) Addiction to tranylcypromine. Br Med J 2: 346
Guscott R, Grof P (1991) The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 148: 695–704
Hindmarch I, Kerr J (1992) Behavioural toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology 106 [Suppl]: S49 — S55
Humberstone PM (1969) Hypertension from cold remedies (letter). Br Med J 1: 846
Jenike MA (1984) The use of monoamine oxidase inhibitors in the treatment of elderly, depressed patients. J Am Geriatr Soc 32: 571–575
Kronig MH, Roose SP, Walsh BT et al. (1983) Blood pressure effects of phenelzine. J Clin Psychopharmacol 3: 307
LE Gassicke J, Ashcroft GW, Eccleston D et al. (1965) The clinical state, sleep, and amine metabolism of a tranylcypromine („parnate“) addict. Br J Psychiatry 1965: 357–364
Liskin B, Roose SP, Walsh BT, Jackson WK (1985) Acute psychosis following phenelzine discontinuation. J Clin Psychopharmacol 5: 46–47
Mann JJ (1983) Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. J Clin Psychopharmacol 3: 363–366
Mason AMS, Buckle RM (1969) „Cold“ cures and monoamine-oxidase inhibitors (letter). Br Med J 1: 845–846
Mattsson A, Seltzer RL (1981) MAOI-induced rapid cycling bipolar affective disorder in an adolescent. Am J Psychiatry 138: 677–679
Moll E, Stabl R, Wegscheider R, Amrein R (1992) Long-term treatment with moclobemide. An open-label, non-comparative, multiple-distributed study in patients with a major depressive episode as defined by DSM-III. Psycho-pharmacology 106 [Suppll: S120 — S122
Neil JF, Licata SM, May SJ et al. (1979) Dietary noncompliance during treatment with tranylcypromine. J Clin Psychiatry 40: 33–37
Physicians’ Desk Reference (1991) Publisher Barnhart ER, Medical Economics Data, Oradell, NJ
Pons G, Schoerlin MP, Tam YK, Moran C, Pfefen JP, Francoual C, Pedarriosse AM, Chavinie J, Olive G (1990) Moclobemide excretion in human breast milk. Br J Clin Pharmacol 29: 27–31
Potter WZ, Rudorfer MV, Manji H (1991) The pharmacologic treatment of depression. N Engl J Med 325: 633–642
Ramaekers JG, Swijgman HF, O’hanlon JF (1992) Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology 106 [Suppll: S62 — S67
Robinson DS, Lerfald SC, Bennett B, Laux D, Devereaux E, Kayser A, Corcella J, Albright D (1991) Maintenance therapies in recurrent depression: new findings. Psychopharmacol Bull 27: 31–39
Rom SD(1985) More on psychosis following phenelzine discontinuation. J Clin Psychopharmacol 5: 360–361
Sargenti CJ, Rizos AL, Jeste DV (1988) Psychotropic drug interactions in the patient with late-onset psychosis and mood disorder, part 1. Psychiatr Clin North Am 11: 235–252
Shopsin B, Kline NS (1976) Monoamine oxidase inhibitors: potential for drug abuse. Biol Psychiatry 11: 451–456
Stefanis CN, Merz-Frei K (1990) Moclobemide (Ro 11–1163) in long-term treatment. Acta Psychiatr Scand 82 [Suppl 360]: 67–68
Sternbach H (1988) Danger of MAOI therapy after fluoxetine withdrawal. Lancet ii: 850–851
Stoeckel K, Pfefen Jp, Mayersohn M, Schoerlin MP, Andressen C, Ohnhaus EE, Frey F, Guen-Tert TW(1990) Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand 82 [Suppl 360]: 94–97
Teicher MH, Cohen BM, Baldessarini RJ, Cole JO (1988) Severe daytime somnolence in patients treated with an MAOI. Am J Psychiatry 145: 1552–1556
Thiels C (1987) Pharmacotherapy of psychiatric disorders in pregnancy and during breast-feeding: a review. Pharmacopsychiatry 20: 133–146
Trott GE, Menzel M, Friese HJ, Nissen G (1991)
Wirksamkeit und Verträglichkeit des selektiven MAO-A-Inhibitors Moclobemid bei Kindern mit hyperkinetischem Syndrom. Z Kinder-Jugendpsychiat 19: 248–253
Trott GE, Friese HJ, Menzel M, Nissen G (1992) Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 106 [Suppl]: S134 — S136
Vartzopoulos D, Krull F (1991) Dependence on monoamine oxidase inhibitors in high dose. Br J Psychiatry 158: 856–857
Walker JI, Davidson J, Zung WWK (1984) Patient compliance with MAO inhibitor therapy. J Clin Psychiatry 45: 78–80
Wesnes KA, Simpson PM, Christmas L, Anand R, Mcclelland GR (1989) The effects of moclobemide on cognition. J Neural Transm [Suppl] 28: 91–102
Youdim MBH, Aronson JK, Green AR, GRAHAMESMITH DG (1979) Tranylcypromine (Tamale’) overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med 9: 377–382
Ananth J, Luchins DA (1977) A review of combined tricyclic and MAOI therapy. Compr Psychiatry 18: 121–134
Beaumont G (1973) Drug interactions with clomipramine (Anafranil). J Int Med Res 1: 480–484
Caglieri-Cingolani R, Bencini A(1982) Due case mortali di reazione tossica per assoziazione di farmace antidepressivi inhibitori delle monoamino-ossidase e tricyclici. Riv Pat Nery Ment 103: 21–31
Carl G, Laux G (1989) Moclobemid in der Langzeitbehandlung Depressiver. Psychiatr Prax16 (Sonderheft): 48–50
Cohen SN, Armstrong MF (1974) Drug interactions: a handbook for clinical use. Williams and Wilkins, Baltimore
Davidson J, Mc Leod M, Law-Yone B, Linnoila M (1978) A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry 35: 639–642
Gander Dr (1965) Treatment of depressive illnesses with combined antidepressants. Lancet is 107–109
Goldberg RS, Thornton WE (1978) Combined tricyclic-MAGI therapy for refractory depression: a review, with guidelines for appropriate usage. J Clin Pharmacol 18: 143–147
Graham PM, Poi1er J M, Paiierson JW (1982) Combination monoamine oxidase inhibitor tricyclic antidepressant interaction. Lancet ii: 440
Kielholz P, Terzani S, Gastpar M (1978) Behandlung der therapieresistenten Depressionen. Dtsch Med Wochenschr 103: 241–243
Korn A, Eichler HG, Fischbach R, Gasic S (1986) Moclobemide, a new reversible MAO inhibitor — interaction with tyramine and tricyclic antidepressants in healty volunteers and depressive patients. Psychopharmacology 88: 153–157
Laux G (1986) Chronifizierte Depressionen. Enke, Stuttgart
Loveless AH, Maxwell DR (1965) A comparison of the effects of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor. Br J Pharmacol 25: 158–170
Marks J (1965) Interaction involving drugs used in psychiatry. In: Marks J, Pare CMB (eds) The scientific basis of drug therapy in psychiatry. Pergamon, Oxford, pp 191–201
Marley E, Wozniak KM (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors. Psychol Med 13: 735–749
MÖller HJ (1991) Therapieresistenz auf Antidepressiva: Risikofaktoren and Behandlungsmöglichkeiten. Nervenarzt 62: 658–669
MÖller HJ, Kissling W, Stoll KD, Wendt G( 1989 ) Psychopharmakotherapie. Kohlhammer, Stuttgart
Murphy Dl, Sunderland T, Cohen RM (1984) Monoamine oxidase-inhibiting antidepressants — a clinical update. Psychiatr Clin North Am 7: 549–562
V. Oefele K, Grohmann R, Hippius H, RÜther E (1988) Unerwünschte Arzneimittelwirkungen bei der Kombinationsbehandlung mit trizykli- schen Antidepressiva und Monoaminoxidase- Hemmern. Nervenarzt 59: 118–123
Pare CMB (1964) Toxicity of psychotropic drugs: side effects and toxic effects of antidepressants. Proc R Soc Med 57: 757–778
Pare Cmb (1979) Monoamine oxidase inhibitors in resistant depression. Int Pharmacopsychiatr 14: 101–109
Pare CMB (1985) The present status of monoamine oxidase inhibitors. Br J Psychiatry 146: 576–584
Peebles-Brown AE (1985) Hyperpyrexia following psychotropic drug overdose. Anaesthesia 40: 1097–1099
PÖldinger W, Alac S, Krebs-Roubicek E(1982) Zur Behandlung therapierefraktärer Depressionen. In: KIELHOLZ P, ADAMS C (Hrsg) Antidepressive Infusionstherapie. Thieme, Stuttgart, S 38–41
Ponto LB, Perry PJ, Liskow BI, Scaba HH (1977) Drug therapy reviews: tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am J Hosp Pharm 34: 955–961
Ray I (1973) Combinations of antidepressant drugs in the treatment of depressive illness. Can Psychiatr Assoc J 18: 399–402
Razzani J, White K, White J, Simpson G, Sloane RB, Rebal R, Palmer R (1983) The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. Arch Gen Psychiatry 40: 657–661
Sargant W, Walter CJS, Wright N (1966) New treatment of chronic tension states. Br Med J 1: 322–324
Schmauss M, Meller J(1989) Die „therapieresistente“ Depression — Ursachen und Behandlungsmöglichkeiten. Psychiatr Prax 16: 101–108
Schmauss M, Kapfhammer HP, Meyr P, Hoff P (1988) Combined MAO-inhibitor and tri(tetra) cyclic antidepressant treatment in therapy resistant depression. Frog Neuropsychopharmacol Biol Psychiatry 12: 523–532
Schuckit M, Robins E, Feighner J (1971) Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry 24: 509–514
Sethna ER (1974) A study of refractory cases of depressive illness and their response to combined antidepressant treatment. Br J Psychiatry 124: 265–272
Sjöqvist F (1965) Psychotropic drugs II. Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med 58: 967–978
Spiker DG, Pugh DD (1976) Combining tricyclic and monoamine oxidase inhibitor antidepressants. Arch Gen Psychiatry 33: 828–830
White K, Simpson G (1981) Combined MAOItricyclic antidepressant treatment. A reevaluation. J Clin Psychopharmacol 1: 264–282
White K, Simpson G (1984) The combined use of MAOIs and tricyclics. J Clin Psychiatry 45: 67–69
White K, Pistole TA, Boyd J (1980) Combined monoamine oxidase inhibitor tricyclic antidepressant treatment. A pilot study. Am J Psychiatry 137: 1422–1425
Winston F (1971) Combined antidepressant therapy. Br J Psychiatry 118: 301–304
Young JPR, Lader MH, Hughes WC (1979) Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 2: 1315–1317
Zimmer R, Gieschke R, Fischbach R, Gasic S (1990) Interaction studies with moclobemide. Acta Psychiatr Scand [Suppl] 360: 84–86
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Wien
About this chapter
Cite this chapter
Gerlach, M. et al. (1993). Monoaminoxidase-Hemmer. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3317-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3317-0_4
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-3318-7
Online ISBN: 978-3-7091-3317-0
eBook Packages: Springer Book Archive